Featured Articles

Evotec SE announced the signing of a definitive agreement under which Evotec will acquire 100% of the capital of Rigenerand Srl, a leading cell technology company, for a purchase price…
Read More...

Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, announced that the U.S. Food and Drug Administration (FDA) approved TIBSOVO …
Read More...

Pfizer Inc. and Biohaven Pharmaceutical Holding Company Ltd. announced that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven, the maker of…
Read More...

Novartis announced that the European Commission (EC) has approved Kymriah (tisagenlecleucel), a CAR-T cell therapy, for the treatment of adult patients with relapsed or refractory (r/r)…
Read More...

Dragonfly Therapeutics, Inc. ("Dragonfly"), a biotechnology company developing novel immunotherapies that harness the innate immune system to treat disease, announced an expansion of…
Read More...

Pfizer Inc. and BioNTech SE announced positive results from a Phase 2/3 clinical trial evaluating the safety, tolerability and immunogenicity of a 10-µg booster (third) dose of the…
Read More...

Astellas Pharma Inc. and Seagen Inc. announced that the European Commission (EC) has approved PADCEV (enfortumab vedotin) as monotherapy for the treatment of adult patients with locally…
Read More...

UCB announced it will build an innovative and environmentally sustainable gene therapy process development and clinical manufacturing facility on their high-tech campus in Braine…
Read More...

Novartis announced a license option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus (AAV) technologies, for three capsids…
Read More...

Pfizer Inc. announced that its respiratory syncytial virus (RSV) vaccine candidate, PF-06928316 or RSVpreF, received Breakthrough Therapy Designation from the US Food and Drug…
Read More...

AbbVie announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. This acquisition gives AbbVie access to…
Read More...

Eli Lilly and Company announced the launch of the Lilly Institute for Genetic Medicine and an investment of approximately $700 million to establish a state-of-the-art facility at a new…
Read More...

AstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union as an add-on therapy for the treatment of adult patients with moderate to severe, active…
Read More...

Pfizer Inc. and OPKO Health, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Biologics License Application (BLA)…
Read More...

Pfizer Inc. and Acuitas Therapeutics, a company focused on developing lipid nanoparticle (LNP) delivery systems to enable messenger RNA (mRNA)-based therapeutics, announced they have…
Read More...

Century Therapeutics and Bristol Myers Squibb announced today a research collaboration and license agreement (the “agreement”) to develop and commercialize up to four induced…
Read More...

Amgen and Generate Biomedicines announced a research collaboration agreement to discover and create protein therapeutics for five clinical targets across several therapeutic areas and…
Read More...

Novo Nordisk announced that the acquisition of Dicerna Pharmaceuticals, Inc. announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk’s cash tender…
Read More...

Merck, a leading science and technology company, announced that it has signed an agreement with biotechnology company Innovative Biotech (IB) to design the manufacturing process for the…
Read More...

Pfizer Inc. and Arena Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical stage company…
Read More...